CORDA Investment Management LLC. Purchases 151 Shares of Abbott Laboratories (NYSE:ABT)

CORDA Investment Management LLC. boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,103 shares of the healthcare product maker’s stock after purchasing an additional 151 shares during the quarter. CORDA Investment Management LLC.’s holdings in Abbott Laboratories were worth $1,708,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Peterson Financial Group Inc. purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $32,000. Valued Wealth Advisors LLC increased its stake in Abbott Laboratories by 78.4% during the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after acquiring an additional 127 shares during the last quarter. Wingate Wealth Advisors Inc. purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $34,000. Highline Wealth Partners LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at approximately $37,000. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $37,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.1 %

NYSE ABT opened at $135.89 on Friday. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $136.99. The company has a 50 day moving average price of $122.60 and a 200 day moving average price of $117.56. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The firm has a market cap of $235.67 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.74%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s payout ratio is currently 30.85%.

Insider Buying and Selling

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Barclays reaffirmed an “overweight” rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Evercore ISI lifted their price target on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a research note on Thursday, January 2nd. Stifel Nicolaus increased their price objective on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $135.00 price target on shares of Abbott Laboratories in a report on Tuesday, January 21st. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $133.06.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.